Ten take-home messages on vasopressin use in critically ill patients

Ricard Ferrer , Pedro Castro , Carol Lorencio , Josman Monclou , Pilar Marcos , Ana Ochagavia , Juan Carlos Ruíz-Rodríguez , Josep Trenado , Christian Villavicencio , Juan Carlos Yébenes , Lluís Zapata , on behalf of the SOCMIC Sepsis Working Group
{"title":"Ten take-home messages on vasopressin use in critically ill patients","authors":"Ricard Ferrer ,&nbsp;Pedro Castro ,&nbsp;Carol Lorencio ,&nbsp;Josman Monclou ,&nbsp;Pilar Marcos ,&nbsp;Ana Ochagavia ,&nbsp;Juan Carlos Ruíz-Rodríguez ,&nbsp;Josep Trenado ,&nbsp;Christian Villavicencio ,&nbsp;Juan Carlos Yébenes ,&nbsp;Lluís Zapata ,&nbsp;on behalf of the SOCMIC Sepsis Working Group","doi":"10.1016/j.medine.2024.09.009","DOIUrl":null,"url":null,"abstract":"<div><div>The most used vasopressors in critically ill patients are exogenous catecholamines, mainly norepinephrine. Their use can be associated with serious adverse events and even increased mortality, especially if administered at high doses. In recent years, the addition of vasopressin has been proposed to counteract the deleterious effects of high doses of catecholamines (decatecholaminization) with the intention of improving the prognosis of these patients. Currently, vasopressin has two main indications: septic shock and vasoplegic shock in the postoperative period of cardiac surgery. In septic shock, current evidence favors its early initiation before reaching high doses of norepinephrine. In the postoperative period of cardiac surgery, the different benefits of the use of vasopressin have been studied, especially in patients with atrial fibrillation and pulmonary hypertension. When used properly, vasopressin is a safe an effective drug for the indications described above.</div></div>","PeriodicalId":94139,"journal":{"name":"Medicina intensiva","volume":"48 12","pages":"Pages 704-713"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina intensiva","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173572724002352","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The most used vasopressors in critically ill patients are exogenous catecholamines, mainly norepinephrine. Their use can be associated with serious adverse events and even increased mortality, especially if administered at high doses. In recent years, the addition of vasopressin has been proposed to counteract the deleterious effects of high doses of catecholamines (decatecholaminization) with the intention of improving the prognosis of these patients. Currently, vasopressin has two main indications: septic shock and vasoplegic shock in the postoperative period of cardiac surgery. In septic shock, current evidence favors its early initiation before reaching high doses of norepinephrine. In the postoperative period of cardiac surgery, the different benefits of the use of vasopressin have been studied, especially in patients with atrial fibrillation and pulmonary hypertension. When used properly, vasopressin is a safe an effective drug for the indications described above.
关于危重病人使用血管加压素的十点启示。
重症患者最常用的血管加压药是外源性儿茶酚胺,主要是去甲肾上腺素。使用这些药物可能会导致严重的不良反应,甚至增加死亡率,尤其是在大剂量使用的情况下。近年来,有人提出添加血管加压素来抵消大剂量儿茶酚胺的有害影响(去甲肾上腺素化),以期改善这些患者的预后。目前,血管加压素有两个主要适应症:脓毒性休克和心脏手术术后的血管性休克。对于脓毒性休克,目前的证据支持在使用大剂量去甲肾上腺素之前尽早使用血管加压素。在心脏手术术后,使用血管加压素的不同益处已得到研究,尤其是在心房颤动和肺动脉高压患者中。如果使用得当,血管加压素在上述适应症中是一种安全有效的药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信